| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018102646 |
| P356 | DOI | 10.1007/S11864-016-0401-9 |
| P932 | PMC publication ID | 5578701 |
| P698 | PubMed publication ID | 27193488 |
| P2093 | author name string | Anas Younes | |
| Eri Matsuki | |||
| P2860 | cites work | CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation | Q37100764 |
| Blinatumomab: A historical perspective | Q38039789 | ||
| Bispecific antibody platforms for cancer immunotherapy | Q38246583 | ||
| Adoptive cellular therapy: a race to the finish line. | Q38391528 | ||
| Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells | Q39548715 | ||
| High-density preculture of PBMCs restores defective sensitivity of circulating CD8 T cells to virus- and tumor-derived antigens | Q40889512 | ||
| Graft-versus-leukemia reactions after bone marrow transplantation | Q41198977 | ||
| Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. | Q41228724 | ||
| PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies | Q41826795 | ||
| Leishmania amastigotes visualized on bone marrow aspirate in a leishmaniasis and HIV coinfected patient presenting with pancytopenia | Q42238772 | ||
| Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells | Q42581359 | ||
| Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study | Q53250473 | ||
| Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody | Q53518554 | ||
| Presence of calreticulin mutations in JAK2-negative polycythemia vera | Q55070722 | ||
| Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement | Q56908957 | ||
| Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors | Q56909582 | ||
| CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms | Q24534904 | ||
| Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | Q24594920 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Lymphoma: immune evasion strategies | Q28080705 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias | Q29622949 | ||
| Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma | Q33386521 | ||
| Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. | Q33632062 | ||
| Current concepts in the diagnosis and management of cytokine release syndrome | Q33886879 | ||
| Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor | Q34041792 | ||
| Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity | Q34326400 | ||
| Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 | Q34360292 | ||
| Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial | Q34391446 | ||
| Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies | Q34592058 | ||
| Cancer immunotherapy: the past, the present and the future | Q35083647 | ||
| Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK | Q35156866 | ||
| Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells | Q35427446 | ||
| Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy | Q35875897 | ||
| Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab | Q35895159 | ||
| Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors | Q36070000 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma | Q36700470 | ||
| Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial | Q36726204 | ||
| Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial | Q36929714 | ||
| Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. | Q36973676 | ||
| P433 | issue | 6 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 31 | |
| P577 | publication date | 2016-06-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Treatment Options in Oncology | Q3510796 |
| P1476 | title | Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma | |
| P478 | volume | 17 |
| Q41928232 | A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response? |
| Q37642460 | From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. |
| Q64274976 | Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas |
| Q64997020 | Microenvironment Cell Contribution to Lymphoma Immunity. |
| Q57176259 | Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) |
| Q90646546 | Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis |
| Q64883255 | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. |
| Q37340738 | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma |
| Q91914786 | Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas |
| Q90407066 | Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring |
| Q91643038 | Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy |
| Q39013616 | Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance |
| Q92717784 | Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials |
| Q47855599 | Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors |
Search more.